Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous sunitinib treatment for symptomatic malignant pleural and/or peritoneal effusions
2007-006459-38Phase 2Completed
- Sponsor
- St. Augustinus Gruppe
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in malignant pleural effusion (MPE) and malignant ascites, sponsored by St. Augustinus Gruppe. Primary endpoint: Non-progression at six weeks of continuous treatment. Started Aug 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
malignant pleural effusion (MPE)malignant ascites
Beyond the preview
Go deeper on 2007-006459-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006459-38.